Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
Most melanomas have BRAF V600E/K mutations, making V600 an important target for precision treatment of melanoma, and it can often be blocked by a combination of BRAF inhibitors and MEK inhibitors. The emergence of immune checkpoint inhibitors has also greatly improved the treatment outcome of patien...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Office of China Oncology
2022-05-01
|
Series: | Zhongguo aizheng zazhi |
Subjects: | |
Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1654759405306-1558543584.pdf |
Summary: | Most melanomas have BRAF V600E/K mutations, making V600 an important target for precision treatment of melanoma, and it can often be blocked by a combination of BRAF inhibitors and MEK inhibitors. The emergence of immune checkpoint inhibitors has also greatly improved the treatment outcome of patients with BRAF V600 mutation-positive advanced melanoma. Clinical trials are also underway to determine the best first-line treatment and the sequence of combination therapies for these patients. This paper reviewed the latest progress in the treatment of BRAF V600 mutation-positive advanced melanoma in the era of precision medicine. |
---|---|
ISSN: | 1007-3639 |